Skip to content
preclinicalImmune & Inflammation

Melittin

Also known as: MEL, Bee Venom Peptide, Apis mellifera venom peptide

Melittin is the principal active component of European honeybee (Apis mellifera) venom, a 26-amino acid amphipathic peptide comprising approximately 50% of dry venom weight. It is one of the most extensively studied membrane-active peptides in biochemistry, with potent antimicrobial, anticancer, and anti-inflammatory properties. Melittin disrupts biological membranes through a detergent-like mechanism, and research is exploring targeted delivery strategies to harness its cytotoxic power for cancer therapy while minimizing off-target toxicity.

3 cited references·6 researched benefits

Quick Answer

Melittin is a 26-amino acid peptide that constitutes the major component of honeybee venom. It disrupts cell membranes through pore formation and has demonstrated anticancer activity against breast, liver, lung, and other cancer cell lines. It also possesses broad-spectrum antimicrobial properties and anti-inflammatory effects. The key challenge is delivering melittin selectively to target cells, as unmodified melittin destroys normal cells indiscriminately. Nanoparticle and antibody-conjugate delivery systems are being developed to address this limitation.

Key Facts

Mechanism
Melittin is an amphipathic alpha-helical peptide with a hydrophobic N-terminal region and a hydrophilic, positively charged C-terminal region. It inserts into lipid bilayers in a voltage-dependent manner, forming toroidal pores that disrupt membrane integrity. At low concentrations, it creates transient pores; at higher concentrations, it acts as a detergent, solubilizing membranes entirely. In cancer cells, melittin activates phospholipase A2, releases arachidonic acid, induces reactive oxygen species (ROS), triggers mitochondrial membrane permeabilization, and activates caspase-mediated apoptosis. It also inhibits NF-kB signaling (reducing inflammation and tumor survival pathways), suppresses matrix metalloproteinases MMP-2 and MMP-9 (reducing metastatic potential), and inhibits VEGF-mediated angiogenesis.
Research Status
preclinical
Half-Life
~minutes in plasma (rapid degradation and membrane binding)
Molecular Formula
C₁₃₁H₂₂₉N₃₉O₃₁
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Broad-spectrum anticancer activity — induces apoptosis in breast, prostate, liver, lung, ovarian, and melanoma cancer cell linesmoderate
  • Potent antimicrobial activity against bacteria, fungi, and enveloped viruses including drug-resistant strains (MRSA, VRE)moderate
  • Anti-inflammatory effects through NF-kB inhibition — reduces TNF-α, IL-1β, and IL-6 in experimental modelsmoderate
  • Synergistic with conventional chemotherapy — enhances drug uptake through membrane permeabilizationpreliminary
  • Nanoparticle-delivered melittin shows selective tumor killing with reduced systemic toxicity in animal modelspreliminary
  • Disrupts biofilms and kills persister cells resistant to conventional antibioticspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research/preclinical only1–10 mcg/kg (animal models)VariableNo established human dosing. Unmodified melittin is too hemolytic for systemic administration. Research focuses on nanoparticle-encapsulated, PEGylated, or antibody-conjugated forms to enable targeted delivery. Bee venom therapy (apitherapy) uses whole venom containing melittin but is not standardized.
Bee venom acupuncture (traditional)0.05–0.1 mL diluted bee venom per point2–3× weeklyTraditional practice in Korean and Chinese medicine. Whole bee venom (containing ~50% melittin) is diluted and injected at acupuncture points. Not FDA-approved; lacks standardized dosing and quality control.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hemolysis — unmodified melittin lyses red blood cells at therapeutic concentrations, the primary barrier to systemic useserious
  • Local pain, swelling, and inflammation at injection site (consistent with bee venom reaction)common
  • Allergic and anaphylactic reactions in bee venom-sensitized individualsserious
  • Non-selective cytotoxicity — damages normal cell membranes alongside target cells without targeted deliveryserious
  • Histamine release from mast cell degranulationcommon

Frequently Asked Questions

Can melittin actually kill cancer cells?
Yes, melittin has demonstrated cytotoxic activity against a wide range of cancer cell lines in laboratory studies, including triple-negative breast cancer, hepatocellular carcinoma, non-small cell lung cancer, prostate cancer, and melanoma. A landmark 2020 study by Duffy et al. showed that melittin rapidly destroyed breast cancer cell membranes within 60 minutes at concentrations that spared normal cells under certain conditions. However, the critical challenge is delivering melittin selectively to tumors in a living organism without damaging normal tissues, particularly red blood cells.
Why is bee venom therapy controversial?
Bee venom therapy (apitherapy) uses whole bee venom — which contains melittin plus dozens of other bioactive compounds — for conditions ranging from arthritis to multiple sclerosis. It is controversial because: (1) whole venom is not standardized, so dose and composition vary; (2) most clinical evidence is from small, poorly controlled studies; (3) serious allergic reactions including anaphylaxis can occur; and (4) there have been deaths associated with bee venom therapy. The anti-inflammatory effects are real but difficult to separate from the general inflammatory stress response to venom.
How are researchers solving melittin's toxicity problem?
Several targeted delivery strategies are in preclinical development: (1) nanoparticle encapsulation — melittin loaded into perfluorocarbon nanoemulsions or lipid nanoparticles that accumulate preferentially in tumors via the EPR effect; (2) antibody-drug conjugates — melittin linked to tumor-targeting antibodies for selective delivery; (3) pro-drug approaches — melittin modified with cleavable linkers that are only activated by tumor-specific enzymes (e.g., matrix metalloproteinases); and (4) PEGylation — PEG coating shields the hemolytic region until the peptide reaches its target. Several of these approaches have shown selective tumor killing with minimal hemolysis in animal models.
Is melittin the same as bee venom?
No. Melittin is the single most abundant peptide in bee venom, comprising about 50% of dry venom weight, but bee venom contains many other bioactive components including phospholipase A2 (12%), apamin (2%), MCD peptide (2%), adolapin, and various enzymes, histamine, and small molecules. Each component has different biological effects. Isolated melittin is available as a research-grade synthetic or purified peptide. The effects of whole bee venom cannot be attributed to melittin alone, and vice versa.

References

  1. 1
    Melittin: a venom-derived peptide with promising anti-cancer properties(2013)PubMed ↗
  2. 2
    Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer(2020)PubMed ↗
  3. 3
    Melittin — a natural peptide with broad-spectrum antimicrobial activity and its potential as an alternative antibiotic(2021)PubMed ↗

Latest Research

Last updated: 2026-02-19